0000769993-20-000005.txt : 20200106 0000769993-20-000005.hdr.sgml : 20200106 20200106193411 ACCESSION NUMBER: 0000769993-20-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200106 DATE AS OF CHANGE: 20200106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDMAN SACHS & CO. LLC CENTRAL INDEX KEY: 0000769993 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36571 FILM NUMBER: 20511732 BUSINESS ADDRESS: STREET 1: 200 WEST STREET CITY: NEW YORK STATE: NY ZIP: 10282 BUSINESS PHONE: 2129021000 MAIL ADDRESS: STREET 1: 200 WEST STREET CITY: NEW YORK STATE: NY ZIP: 10282 FORMER NAME: FORMER CONFORMED NAME: GOLDMAN SACHS & CO DATE OF NAME CHANGE: 19931102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOLDMAN SACHS GROUP INC CENTRAL INDEX KEY: 0000886982 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36571 FILM NUMBER: 20511733 BUSINESS ADDRESS: STREET 1: 200 WEST STREET CITY: NEW YORK STATE: NY ZIP: 10282 BUSINESS PHONE: 212-902-1000 MAIL ADDRESS: STREET 1: 200 WEST STREET CITY: NEW YORK STATE: NY ZIP: 10282 FORMER NAME: FORMER CONFORMED NAME: GOLDMAN SACHS GROUP INC/ DATE OF NAME CHANGE: 20010104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: T2 Biosystems, Inc. CENTRAL INDEX KEY: 0001492674 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204827488 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-457-1200 MAIL ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 ownershipdoc01062020012629.xml X0306 4 2020-01-02-05:00 false 0001492674 T2 Biosystems, Inc. TTOO 0000886982 GOLDMAN SACHS GROUP INC 200 WEST STREET NEW YORK NY 10282 false false true false 0000769993 GOLDMAN SACHS & CO. LLC 200 WEST STREET NEW YORK NY 10282 false false true false Common Stock 2020-01-02-05:00 4 A false 34188 0 A 4270641 I See footnotes Non-Qualified Stock Option (Right to Buy) 8.92 2026-03-09-04:00 Common Stock 66176 66176 I See footnotes Stock Option (Right to Buy) 1.54 2029-06-07-04:00 Common Stock 22000 22000 I See footnotes This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group. The Reporting Persons disclaim beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, if any. The 34,188 shares of common stock, par value $0.001 per share (the "Common Stock"), were granted pursuant to T2 Biosystems, Inc.'s (the "Company") Amended and Restated 2014 Incentive Award Plan under the Company's Non-Employee Director Compensation Program (the "Plan"), consisting of 34,188 restricted stock units granted to Adrian M. Jones a managing director of Goldman Sachs, in his capacity as a director of the Company. The grant of 34,188 restricted stock units shall become fully vested on January 2, 2021, subject to the Reporting Person continuing in service on the Company's board of directors through such vesting date. Each restricted stock unit represents a contingent right to receive one share of the Company's Common Stock. Mr. Jones has an understanding with GS Group pursuant to which he holds such securities for the benefit of GS Group. GS Group may be deemed to beneficially own 4,270,641 shares of common stock by reason of 34,188 restricted stock units that were granted to Mr. Jones pursuant to the Plan. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of common stock of the Company by reason of the direct beneficial ownership of common stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock. The options to purchase 66,176 shares of common stock of the Company were granted to Mr. Jones in his capacity as a director of the Company pursuant to the Plan. The options vested on March 9, 2019. Mr. Jones has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group. The options to purchase 22,000 shares of common stock of the Company were granted to Mr. Jones, pursuant to the Plan on June 7, 2019 in his capacity as a director of the Company. The options vest and become exercisable in twelve substantially equal monthly installments commencing on June 7, 2019. Mr. Jones has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group. /s/ Jamison Yardley, Attorney-in-fact 2020-01-06-05:00 /s/ Jamison Yardley, Attorney-in-fact 2020-01-06-05:00